Effect of pioglitazone on decreasing of proteinuria in type 2 diabetic patients with nephropathy.


- Diabetic nephropathy means albuminuria greater than 30 mg/day and it affects about one third of diabetic patients.
- The study was conducted to investigate the effect of pioglitazone on reduction in proteinuria in type 2 DM patients and nephropathy.
- In a double blind trial on 76 patients with type 2 DM with proteinuria greater than 250 mg/d were enrolled in 2 equal groups; one were administered 15mg/d of pioglitazone and the other placebo and the urinary protein excretion over 24h in all the patients was measured.
- Pioglitazone had considerable effects on FBS, HbA1c & Triglycerides which were statistically significant.
- After 2 months the urinary protein excretion in the pioglitazone was significantly reduced as compared to the control group.

Low dose of pioglitazone is an effective, safe and inexpensive method in reducing of proteinuria in type2 diabetic patients with nephropathy.